Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologist who treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial (www.pipelinereview.com)
Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit (www.nytimes.com)
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer (www.pipelinereview.com)
The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer (www.pipelinereview.com)
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO (www.pipelinereview.com)
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs (online.wsj.com)
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
Analysis of: China Muscles In On The Generics Industry (www.pharmalot.com)
China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...
Analysis of: Drug Brings ImClone in From Cold (online.wsj.com)
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study (online.wsj.com)
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
Analysis of: Hints of Progress in Drugs Treating Brain Cancer (www.nytimes.com)
For the first time in decades, several drugs like Temodar and Avastin and tumor vaccines ( Avant and others) have shown increased overall survival even in adavnaced and recurrent brain tumors as glioblastoma multiforme. Several agents are in the pipeline, and more Big Pharma involvement is expected...

Previous Page : 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next111 to 120 of 773

Analytics


Generated at 2009-01-07T13:00:17.563